Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Overview Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Companies Involved in Therapeutics Development Basilea Pharmaceutica Ltd Millennium Pharmaceuticals Inc Novartis AG Redx Pharma Plc Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Drug Profiles BAL-3833 - Drug Profile Product Description Mechanism Of Action R&D Progress LXH-254 - Drug Profile Product Description Mechanism Of Action R&D Progress REDX-05358 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress TAK-580 - Drug Profile Product Description Mechanism Of Action R&D Progress Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Discontinued Products Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Product Development Milestones Featured News & Press Releases Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec Sep 07, 2004: Biogen Idec And Sunesis Form Collaboration To Discover And Develop Multiple Small Molecule Oncology Products Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Basilea Pharmaceutica Ltd, H1 2018 Pipeline by Millennium Pharmaceuticals Inc, H1 2018 Pipeline by Novartis AG, H1 2018 Pipeline by Redx Pharma Plc, H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018

Basilea Pharmaceutica Ltd Millennium Pharmaceuticals Inc Novartis AG Redx Pharma Plc